Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.55 |
| ▸ | HTR2C | P28335 | 1/20 | 0.55 |
| ▸ | HTR7 | P34969 | 3/20 | 0.54 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.45 |
| ▸ | PLG | P00747 | 1/20 | 0.44 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
| ▸ | KRAS | P01116 | 5/20 | 0.42 |
| ▸ | CDK4 | P11802 | 3/20 | 0.41 |
| ▸ | CCND1 | P24385 | 3/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31121493 | 0.86 | HTR7 (0.54) | HTR2AHTR2CHTR7CDK4CCND1 | |
| SCHEMBL5621531 | 0.86 | HTR7 (0.54) | HTR2AHTR2CHTR7CDK4CCND1 | |
| SCHEMBL849554 | 0.84 | HTR2A (0.48) | HTR2AHTR2CHTR7NTSR1PLG | |
| SCHEMBL27382854 | 0.82 | PLAU (0.47) | HTR2AHTR2CHTR7PLGPLAU | |
| SCHEMBL14061899 | 0.82 | HTR2A (0.59) | HTR2AHTR2CHTR7NTSR1PLG | |
| SCHEMBL21941497 | 0.82 | HTR2A (0.59) | HTR2AHTR2CHTR7NTSR1PLG | |
| SCHEMBL29758270 | 0.80 | KMO (0.56) | HTR2AHTR2CHTR7NTSR1KRAS | |
| SCHEMBL19100386 | 0.80 | KMO (0.56) | HTR2AHTR2CHTR7NTSR1KRAS | |
| SCHEMBL4939152 | 0.79 | HTR2A (0.56) | HTR2AHTR2CHTR7NTSR1PLG | |
| SCHEMBL30729445 | 0.79 | HTR2A (0.56) | HTR2AHTR2CHTR7NTSR1PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146035-A1 | FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS | DONG-A ST CO., LTD. (KR) | 2026-05-28 | — | — | US | disclosed |
| EP-4605395-A2 | FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS | Dong-A ST Co., Ltd. (KR) | 2025-08-27 | — | — | EP | disclosed |
| WO-2024084448-A2 | FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS | DONG-A ST CO., LTD. (KR) | 2024-04-25 | — | — | WO | disclosed |
| EP-3924343-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS | Merck Sharp & Dohme Corp. (US) | 2021-12-22 | — | — | EP | disclosed |
| US-20160130226-A1 | SPIRO-SUBSTITUTED OXINDOLE DERIVATIVES HAVING AMPK ACTIVITY | CONNEXIOS LIFE SCIENCES PVT. LIMITED (IN) | 2016-05-12 | — | — | US | disclosed |
| US-20160130226-A1 | SPIRO-SUBSTITUTED OXINDOLE DERIVATIVES HAVING AMPK ACTIVITY | CONNEXIOS LIFE SCIENCES PVT. LIMITED (IN) | 2016-05-12 | — | — | US | disclosed |
| US-20160130226-A1 | SPIRO-SUBSTITUTED OXINDOLE DERIVATIVES HAVING AMPK ACTIVITY | CONNEXIOS LIFE SCIENCES PVT. LIMITED (IN) | 2016-05-12 | — | — | US | disclosed |
| EP-3010905-A1 | SPIRO-SUBSTITUTED OXINDOLE DERIVATIVES HAVING AMPK ACTIVITY | Boehringer Ingelheim International GmbH (DE) | 2016-04-27 | — | — | EP | disclosed |
| WO-2014202580-A1 | SPIRO-SUBSTITUTED OXINDOLE DERIVATIVES HAVING AMPK ACTIVITY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-24 | — | — | WO | disclosed |
| WO-2014202580-A1 | SPIRO-SUBSTITUTED OXINDOLE DERIVATIVES HAVING AMPK ACTIVITY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-24 | — | — | WO | disclosed |
| US-20020183348-A1 | For use as drugs | CHU DANIEL (US) | 2002-12-05 | — | — | US | disclosed |
| US-20020065295-A1 | Novel polyketide derivatives | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-05-30 | — | — | US | disclosed |
| WO-2001087884-A2 | POLYKETIDE DERIVATIVES | KOSAN BIOSCIENCES, INC. (US) | 2001-11-22 | — | — | WO | disclosed |
| EP-0532088-B1 | O-Heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroaryl macrolides | MERCK & CO INC (US) | 1996-12-04 | — | — | EP | disclosed |
| US-5352783-A | Treating autoimmune diseases | MERCK & CO., INC. (US) | 1994-10-04 | — | — | US | disclosed |
| US-5349061-A | O-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylmacrolides having immunosuppressive activity | MERCK & CO., INC. (US) | 1994-09-20 | — | — | US | disclosed |
| US-5310901-A | Autoimmune diseases; antiinflammatory agents; fungicides; prevention of organ transplant rejection; alkylation and/or arylation at C-42 | MERCK & CO., INC. (US) | 1994-05-10 | — | — | US | disclosed |
| US-5252732-A | D-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylmacrolides having immunosuppressive activity | MERCK & CO., INC. (US) | 1993-10-12 | — | — | US | disclosed |
| WO-1993005058-A1 | O-HETEROARYL, O-ALKYLHETEROARYL, O-ALKENYLHETEROARYL AND O-ALKYNYLHETEROARYLMACROLIDES | MERCK & CO., INC. (US) | 1993-03-18 | — | — | WO | disclosed |
| EP-0532088-A1 | O-Heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroaryl macrolides | MERCK & CO. INC. (US) | 1993-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183348-A1 | For use as drugs | HSD17B14, CYP3A4, CYP3A5 | HTR2A 3345/4885HTR2C 2436/4885HTR7 2131/4885 |
| US-20260146035-A1 | FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS | AXL, ERBB2, ERBB3 | HTR2A 2712/4885HTR2C 1692/4885HTR7 2144/4885 |
| US-20020065295-A1 | Novel polyketide derivatives | HSD17B14, RIOX2, MRPL21 | HTR2A 4270/4885HTR2C 3986/4885HTR7 3557/4885 |
| US-20160130226-A1 | SPIRO-SUBSTITUTED OXINDOLE DERIVATIVES HAVING AMPK ACTIVITY | AK2, PRKAA2, PRKAA1 | HTR2A 977/4885HTR2C 1186/4885HTR7 2573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.